Description of the Tranquillo Phase 3 Clinical Trial Designs/Study Protocols to Assess Ritlecitinib in Adults and Adolescents with Nonsegmental Vitiligo.
Saved in:
| Title: | Description of the Tranquillo Phase 3 Clinical Trial Designs/Study Protocols to Assess Ritlecitinib in Adults and Adolescents with Nonsegmental Vitiligo. |
|---|---|
| Authors: | Lukic T; Pfizer Inc, New York, NY, USA., Ghosh P; Pfizer Inc, Cambridge, MA, USA., Napatalung L; Pfizer Inc, New York, NY, USA.; Mount Sinai Hospital, New York, NY, USA., Wang C; Pfizer Inc, Groton, CT, USA., Kurosky SK; Pfizer Inc, New York, NY, USA., Hamzavi I; Henry Ford Health, Detroit, MI, USA., Sinclair R; University of Melbourne, Melbourne, VIC, Australia.; Sinclair Dermatology, East Melbourne, VIC, Australia., Xiang L; Huashan Hospital, Fudan University, Shanghai, China., Steil K; CCT Research, Scottsdale, AZ, USA.; University of Arizona, Phoenix, AZ, USA., Rosmarin D; Indiana University School of Medicine, Indianapolis, IN, USA., Parsad D; Postgraduate Institute of Medical Education and Research, Chandigarh, India., Ezzedine K; Université Paris-Est Créteil, Créteil, France.; Henri-Mondor University Hospital, Créteil, France., Adiri R; Pfizer Pharmaceutical Israel Ltd, Arye Shenkar St 9, 4672509, Herzliya, Israel. Roni.Adiri@pfizer.com. |
| Source: | Dermatology and therapy [Dermatol Ther (Heidelb)] 2026 Jul; Vol. 16 (7), pp. 3709-3727. Date of Electronic Publication: 2026 May 22. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Healthcare Communications Country of Publication: Switzerland NLM ID: 101590450 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8210 (Print) NLM ISO Abbreviation: Dermatol Ther (Heidelb) Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
